AbbVie
$259.90Change from previous close: −0.65%Absolute change: −$1.69
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $459.81B
- Enterprise value
- $526.62B
- P/E (trailing 12 months)
- 73.3
- Forward P/E
- 16.0
- PEG
- 0.54
- Price/sales
- 7.14
- EV/EBITDA
- 17.1
- EV/revenue
- 8.18
Profitability and growth
- Gross margin
- 72.8%
- Operating margin
- 40.0%
- Net margin
- 9.8%
- ROA
- 10.5%
- Revenue growth (year over year)
- 10.2%
- Earnings growth (year over year)
- 290.4%
Financial health
- Total cash
- $6.57B
- Total debt
- $70.88B
- Current ratio
- 0.81
- Quick ratio
- 0.49
Dividends
- Annual dividend per share
- $6.92
- Dividend yield
- 2.7%
- Payout ratio
- 190.4%
- Ex-dividend date
- October 15, 2026
Analysts and estimates
- Average price target
- $278.86
- Median price target
- $285.00
- High price target
- $328.00
- Low price target
- $200.00
- Analysts with a price target
- 28
- Consensus
- Buy
- Forward EPS
- $16.27
- EPS estimate, current year
- $14.01
Shares and trading
- Beta
- 0.28
- Average volume
- 4.97M
- Shares outstanding
- 1.77B
- Float
- 1.76B
- Institutional ownership
- 77.3%
- Insider ownership
- 0.1%
- Short interest (% of float)
- 1.2%
- Short ratio (days)
- 4.44